Camrelizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | PD1 |
| Clinical data | |
| Other names | SHR-1210 |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Camrelizumab (INN;[1] development code SHR-1210) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma.[2] PD-1 is programmed cell death protein 1.
The drug is being developed by Jiangsu HengRui Medicine Co., Ltd. As of 2019, camrelizumab is undergoing Phase II/III trials.
In China, in May 2025 camrelizumab was conditionally approved for use in combination with famitinib for the treatment of recurrent or metastatic cervical cancer in patients who have failed prior platinum-based chemotherapy and have not received prior bevacizumab.[3]
Camrelizumab was approved in Russia in November 2024 under the brand name Areima. Its approved indications include certain forms of esophageal cancer, nasopharyngeal carcinoma, NSCLC, and TNBC.[4]
References
- ↑ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77" (PDF). WHO Drug Information. 31 (1).
- ↑ Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, et al. (June 2019). "Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma". Journal of Clinical Oncology. 37 (17): 1479–1489. doi:10.1200/JCO.18.02151. PMID 31039052. S2CID 141482897.
{{cite journal}}: CS1 maint: overridden setting (link) - ↑ Keam SJ (2025). "Famitinib: First Approval". Drugs. 85 (12): 1613–1620. doi:10.1007/s40265-025-02238-1. PMID 40996477.
- ↑ "Areima (camrelizumab) for injection, for intravenous use. Full Prescribing Information". Государственный реестр лекарственных средств (in Russian). Ministry of Health of the Russian Federation. Retrieved 19 August 2026.